Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Wearable), Technology (Manual, Automatic), Application (Arthritis, Diabetes, Osteoporosis), Distribution, Route of Administration, End User – Global Forecast to 2031

The Autoinjectors Market was valued at $2.01  billion in 2023. This market is expected to reach $3.76  billion by 2031, from an estimated $2.16  billion in 2024, at a CAGR of 8.3% during the forecast period 2024-2031.

Autoinjectors Market Size & Forecast

The growth of this market is primarily driven by the increasing prevalence of chronic & autoimmune diseases, the growing demand for self-administration of medicines, and technological advancements in autoinjectors. Moreover, the growing demand for home healthcare and partnerships & collaborations by market players are expected to generate market growth opportunities.

Autoinjectors Market Growth Drivers

Increasing Prevalence of Chronic & Autoimmune Diseases

Autoinjectors are utilized to treat various chronic diseases, including diabetes, osteoporosis, and rheumatoid arthritis, as well as autoimmune diseases and adverse occurrences. For instance:

• According to the International Diabetes Federation, in 2021, 537 million people were diagnosed with diabetes worldwide. Among these, the Western Pacific region accounted for 206 million cases, while Southeast Asia accounted for 90 million, the Middle East & North Africa for 73 million, Europe for 61 million, North America & the Caribbean for 51 million, South and Central America for 32 million, and Africa for 24 million. This number is projected to reach 643 million in 2030 and 783 million in 2045.
• According to the World Health Organization’s (WHO) 2023 data, 18 million people had rheumatoid arthritis in 2019.
• According to a 2023 survey conducted by the International Osteoporosis Foundation (IDF), 43% of women respondents reported having fractured a bone after a simple fall and bump after the age of 50. The percentages were the highest in Japan (73.3%) and the U.K. (60.9%) and lowest in Brazil (21.6%).

Thus, the increasing incidence of chronic & autoimmune diseases is boosting the demand for autoinjectors for proper medication.

Click here to: Get a Free Sample Copy of this Report

Technological Advancements in Autoinjectors

Advancements in autoinjector technology have improved their safety and reliability. Advanced autoinjectors include features that maintain proper dosage precision and avoid accidental needlestick injuries. For instance, needle-retraction systems withdraw the needle after injection to reduce needlestick injuries. Autoinjectors have progressively become more user-friendly. Companies have invested in design innovation to simplify the distribution and use of autoinjectors. These devices are lightweight, small, and have simple mechanics that allow patients to self-administer medication with minimal discomfort and effort.

Moreover, many autoinjectors now have connectivity features that allow them to communicate with smartphones and other devices. This connectivity allows for the gathering of information about injection history, medicine use, and patient adherence. These technological advances in autoinjector performance and design have enhanced treatment adherence, patient experience, and overall safety, driving the adoption of autoinjectors.

Autoinjectors Market Opportunities

Partnerships & Collaborations by Market Players

Market players are focusing on partnerships and collaborations due to the increasing demand for autoinjectors. New and advanced products are being introduced into the market to reduce needle phobia and improve patient compliance. For instance:

• In January 2024, FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (U.S.) partnered with SHL Medical AG (Switzerland) to cater to the growing market demand for autoinjectors.

• In May 2023, MoonLake Immunotherapeutics AG (Switzerland) collaborated with SHL Medical AG (Switzerland) to develop an autoinjector for the commercial and clinical supply of MoonLake’s Nanobody Sonelokimab.
• In May 2022, Stevanato Group S.p.A. (Italy) partnered with Owen Mumford Limited (U.K) for its Aidaptus autoinjector.
• In November 2021, Gerresheimer AG (Germany) partnered with Midas Pharma GmbH (Germany) to market and develop a new-generation autoinjector.

Thus, increasing partnerships & collaborations by market players are generating opportunities for market expansion.

Growing Demand for Home Healthcare

Self-administration enables patients by allowing them to actively participate in their medical treatment. It reduces the need for frequent visits to medical centers for medicine delivery, easing the strain on both doctors and patients. Autoinjectors are portable and simple to use, which makes them ideal for patients to carry and self-administer medication as needed.

People develop various chronic diseases as they age, necessitating drug management. Autoinjectors make drug administration easier for older adults who have limited physical acuity. The ease of use and simplicity provided by autoinjectors make them an appealing option for this age group. According to a report published by the Joint Center for Housing Studies at Harvard University, by 2035, one in every three American households will be headed by individuals aged 65 or older. Thus, high hospitalization costs, the growing aging population, and the rising need for personal medical care are driving the demand for home healthcare services and autoinjectors.

Autoinjectors Market Trends

Smart/Electronic Autoinjectors

Smart/electronic autoinjectors use Wi-Fi, Bluetooth, and mobile apps to communicate with smartphones and other devices. This interaction allows for data analysis, collection, and exchange. Patients get reminders for medication and information on injection history and can share information with doctors to improve treatment management. Telemedicine and digital health systems can be coupled with smart autoinjectors to enhance remote monitoring.

Smart autoinjectors offer benefits such as dose customization and personalization, real-time guidance, and improved medication and treatment outcomes. Furthermore, various companies are focusing on launching smart autoinjectors. For instance, in May 2021, Phillips-Medisize (U.S.) launched the Aria Smart Autoinjector platform to unlock differentiation and sustainability in the digital drug-delivery devices market.

Autoinjectors Market Analysis: Key Findings

By Type: The Disposable Autoinjectors Segment to Dominate the Autoinjectors Market in 2024

Based on type, the autoinjectors market is segmented into disposable autoinjectors, reusable autoinjectors, smart autoinjectors, and wearable autoinjectors. In 2024, the disposable autoinjectors segment is expected to account for the largest share of 51.7% of the autoinjectors market. The large market share of this segment can be attributed to the advantages of disposable autoinjectors over other types, such as automatic safety features, ease of use (especially for patients with low dexterity), audible and visual feedback indicators, consistent injection activation, complete injection, and controlled injection depth. Furthermore, the companies operating in this market are focused on introducing innovative offerings to cater to the rising demand for autoinjectors. For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. (Japan) launched the Nanozora 30mg Autoinjector for S.C. Injection, a single-use autoinjector dosage form, to prevent needle piercing accidents. Such developments are contributing to the segment’s large share.

However, the smart autoinjectors segment is projected to register the highest CAGR of 9.7% during the forecast period 2024-2031. The growth of this segment is driven by technological advancements in autoinjectors and the benefits of smart autoinjectors, such as dosage accuracy through prefilled medication, reduced anxiety due to minimal needle injuries, and improved patient compliance and medication adherence.

By Route of Administration: The Subcutaneous Segment to Dominate the Autoinjectors Market in 2024

Based on route of administration, the autoinjectors market is segmented into subcutaneous and intramuscular. In 2024, the subcutaneous segment is expected to account for the larger share of the autoinjectors market. The segment’s large market share can be attributed to the availability of a large number of drugs that are administered subcutaneously, and the increasing number of new drugs being launched for subcutaneous self-administration. For instance, in May 2022, Jabil, Inc. (U.S.) launched Qfinity, a modular solution for subcutaneous (SC) drug self-administration and a reusable autoinjector platform, to support drug delivery in the pharmaceutical industry. Such developments are expected to support the growth of this segment in the coming years.

By Technology: The Manual Autoinjectors Segment to Dominate the Autoinjectors Market in 2024

Based on technology, the autoinjectors market is segmented into manual autoinjectors and automatic autoinjectors. In 2024, the manual autoinjectors segment is expected to account for the larger share of the autoinjectors market. The segment’s large market share can be attributed to the increasing adoption of manual autoinjectors due to their lower prices compared to automatic injectors, ease of use, and ability to provide controlled and precise dosing.

By Application: The Diabetes Segment to Dominate the Autoinjectors Market in 2024

Based on application, the autoinjectors market is segmented into rheumatoid arthritis, osteoporosis, diabetes, multiple sclerosis, and other applications. In 2024, the diabetes segment is expected to account for the largest share of the autoinjectors market. The segment’s large market share can be attributed to the increasing number of insulin-dependent patients and the rising number of diabetes cases. For instance, according to the International Diabetes Federation, 537 million people were diagnosed with diabetes globally in 2021. This number is expected to increase to 783 million in 2045. Thus, the increasing number of diabetes cases contributes to the segment’s large market share.

By Distribution Channel: The Retail Pharmacies Segment to Dominate the Autoinjectors Market in 2024

Based on distribution channel, the autoinjectors market is segmented into hospital pharmacies, retail pharmacies, and online/e-commerce platforms. In 2024, the retail pharmacies segment is expected to account for the largest share of the autoinjectors market. The large market share of this segment can be attributed to the availability of a diverse selection of autoinjectors at retail pharmacies, which enables patients to choose the most suitable autoinjector based on their specific preferences, needs, and healthcare expert recommendations. The wide variety of autoinjector options available at retail pharmacies ensures that patients can purchase autoinjectors that best suit their needs.

By End User: The Home Care Segment to Dominate the Autoinjectors Market in 2024

Based on end user, the autoinjectors market is segmented into home care, hospitals & clinics, and other end users. In 2024, the home care segment is expected to account for the largest share of 57.6% of the autoinjectors market. The large market share of this segment can be attributed to the increasing adoption of home care devices due to their convenience, precision, and accuracy. Additionally, market players have increased their focus on raising awareness about diseases such as diabetes and rheumatoid arthritis, driving the adoption of autoinjectors in home care settings.

Furthermore, this segment is also projected to register the highest CAGR of 8.8% during the forecast period 2024-2031. Patients’ increasing preference for the self-administration of medications and technological advancements in autoinjectors are driving the growth of this segment.

Geographic Analysis

By Geography: North America to Dominate the Autoinjectors Market in 2024

In 2024, North America is expected to account for the largest share of 36.5% of the autoinjectors market, followed by Europe and Asia-Pacific. North America’s significant market share can be primarily attributed to the presence of major autoinjector manufacturers such as Halozyme, Inc. (U.S.) and Becton, Dickinson and Company (U.S.), the increasing demand for self-administration of drugs, technological advancements in autoinjectors, and the increasing cases of diabetes, osteoporosis, and rheumatoid arthritis in the region.

However, Asia-Pacific is slated to register the highest CAGR of 8.8% during the forecast period. The growth of this regional market is driven by the growing awareness about autoinjectors, the increasing number of awareness programs focusing on autoimmune diseases in countries such as China and India, and the growing healthcare infrastructure in the region.

Autoinjectors Market: Key Companies

The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last 3–4 years. Some of the key players operating in the autoinjectors market are Becton, Dickinson and Company (U.S.), Ypsomed AG (Switzerland), SHL Medical (Switzerland), Recipharm AB (Sweden), Owen Mumford Limited (U.K), Halozyme, Inc. (U.S.), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Solteam Incorporation Co., Ltd. (China), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Bayer AG (Germany), and Union Medico ApS. (Denmark).

Autoinjectors Industry Overview: Latest Developments from Key Industry Players

• In October 2023, ALTAVIZ (U.S.) launched AltaVISC, a new autoinjector platform for next-generation therapies.

• In May 2023, Coherus BioSciences, Inc. (U.S.) launched the UDENYCA (pegfilgrastim-cbqv), single-dose (6mg/0.6mL), prefilled autoinjector to decrease the incidence of infection as displayed by febrile neutropenia.

• In May 2023, C.H. Boehringer Sohn AG & Co. KG (Germany) received the U.S. Food and Drug Administration (FDA) approval for its Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm) to treat multiple chronic inflammatory diseases.
• In April 2020, Teva Pharmaceuticals USA, Inc. (U.S.) launched an autoinjector device for the AJOVY (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults in the U.S.

Autoinjectors Market Research Summary

Key questions answered in the autoinjectors market report: